ARFXF News and Press, Amorfix Life Sciences Ltd From 09/03/19

Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA , Sept. 3, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics ...

Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...

TORONTO and CAMBRIDGE, MA , Aug. 27, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CAMBRIDGE, MA , Aug. 13, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused o...

Alzheimer's Association International Conference includes oral session on PMN310 for Alzheimer's disease and poster presentation on ALS TORONTO and CAMBRIDGE, MA , July 18, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on ...

ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference Canada NewsWire TORONTO and CAMBRIDGE, MA, July 10, 2019 Abstracts selected for oral and poster presentation TORONTO and CAMBRIDGE, MA, July 10, 2019 /CNW/ - ProMIS Ne...

Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease TORONTO and CAMBRIDGE, MA , July 9, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a...

Data presented at Keystone Symposium on Neurodegenerative Diseases TORONTO and CAMBRIDGE, MA , June 27, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxi...

ProMIS Neurosciences Closing Private Placement Canada NewsWire TORONTO, June 26, 2019 /NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO , June 26, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biote...

ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board Canada NewsWire TORONTO and CAMBRIDGE, MA, June 19, 2019 Internationally recognized leader in neurodegenerative diseases to advise on programs selectively ta...